Implementation of a Risk-Stratified Opioid and Benzodiazepine Weaning Protocol in a Pediatric Cardiac ICU
Rambod Amirnovin1, L Nelson Sanchez-Pinto2, Carol Okuhara3
1Department of Anesthesiology and Critical Care Medicine, Children's Hospital Los Angeles, Los Angeles, CA.
Insights
A new protocol reduced opioid and benzodiazepine exposure in critically ill children with heart disease. This led to shorter treatment durations, fewer withdrawal symptoms, and reduced hospital stays.
Area of Science:
- Pediatric critical care medicine
- Cardiology
- Pharmacology
Background:
- Opioids and benzodiazepines are standard for analgesia and sedation in critically ill children with cardiac conditions.
- These medications carry risks, including delirium, dependence, withdrawal, and potential neurodevelopmental issues.
Purpose of the Study:
- To implement a risk-stratified weaning protocol for opioids and benzodiazepines.
- To reduce medication exposure in pediatric patients with cardiac disease.
Main Methods:
- A prospective pre- and postinterventional study design was used.
- An evidence-based opioid and benzodiazepine weaning protocol was implemented using educational and quality improvement methods.
- The study included critically ill children (≤21 years) with cardiac disease receiving scheduled opioids ± benzodiazepines for ≥7 days.
Main Results:
- The postintervention group showed significantly shorter durations of opioid (19.0 vs 30.0 days) and benzodiazepine (5.3 vs 22.7 days) use.
- Withdrawal occurrence decreased (4.9% vs 14.1%) despite shorter weaning durations.
- Hospital length of stay was reduced by 8 days (34 vs 42 days).
Conclusions:
- Implementation of a risk-stratified weaning protocol effectively reduced opioid and benzodiazepine exposure in critically ill pediatric cardiac patients.
- The protocol led to decreased withdrawal symptoms and a shorter hospital length of stay.
- This approach offers a strategy to mitigate adverse effects associated with prolonged sedative and analgesic use in this vulnerable population.
Objectives:
Opioids and benzodiazepines are commonly used to provide analgesia and sedation for critically ill children with cardiac disease. These medications have been associated with adverse effects including delirium, dependence, withdrawal, bowel dysfunction, and potential neurodevelopmental abnormalities. Our objective was to implement a risk-stratified opioid and benzodiazepine weaning protocol to reduce the exposure to opioids and benzodiazepines in pediatric patients with cardiac disease.
Design:
A prospective pre- and postinterventional study.
Patients:
Critically ill patients less than or equal to 21 years old with acquired or congenital cardiac disease exposed to greater than or equal to 7 days of scheduled opioids ± scheduled benzodiazepines between January 2013 and February 2015.
Setting:
A 24-bed pediatric cardiac ICU and 21-bed cardiovascular acute ward of an urban stand-alone children's hospital.
Intervention:
We implemented an evidence-based opioid and benzodiazepine weaning protocol using educational and quality improvement methodology.
Measurements And Main Results:
One-hundred nineteen critically ill children met the inclusion criteria (64 post intervention, 55 pre intervention). Demographics and risk factors did not differ between groups. Patients in the postintervention period had shorter duration of opioids (19.0 vs 30.0 d; p < 0.01) and duration of benzodiazepines (5.3 vs 22.7 d; p < 0.01). Despite the shorter duration of wean, there was a decrease in withdrawal occurrence (% Withdrawal Assessment Tool score ≥ 4, 4.9% vs 14.1%; p < 0.01). There was an 8-day reduction in hospital length of stay (34 vs 42 d; p < 0.01). There was a decrease in clonidine use (14% vs 32%; p = 0.02) and no change in dexmedetomidine exposure (59% vs 75%; p = 0.08) in the postintervention period.
Conclusions:
We implemented a risk-stratified opioid and benzodiazepine weaning protocol for critically ill cardiac children that resulted in reduction in opioid and benzodiazepine duration and dose exposure, a decrease in symptoms of withdrawal, and a reduction in hospital length of stay.
More Related Videos
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
08:42Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression
Published on: May 19, 2015
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Stratified Sampling Method
To choose a stratified sample, divide the population into groups called strata and then take a...
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Opioid Receptors: Overview
CNS Depressants: Barbiturates and Benzodiazepines
Anxiolytic Drugs: Benzodiazepines and Buspirone
